Comparison of Supraneural and Infraneural Transforaminal nerve root injections using ultrasound and Flouroscopic confirmation

Fluoroscopic assessment of feasibility, accuracy and safety of ultrasound-guided supraneural and infraneural transforaminal nerve root injections-a comparative study. - NIL

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064338

Enrollment

Registered

2024-03-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Infraneural: Infraneural Transforaminal Epidural steroid injections using ultrasound and confirmed by flouroscopy Intervention2: Supraneural: Supraneural Transforaminal Epidural steroid

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of either gender between the ages of 18 – 70 years. 2. Patients with BMI between 18 and 35. 3. Patients with ASA grading I & II 4. Patients with back pain of discogenic origin, with or without discomfort to the particular dermatomal distribution, whose activities are restricted for at least six weeks and who do not respond to conservative treatment. 5. Neurogenic claudication. 6. MRI results indicating a nerve root involvement or a positive laesegue sign.

Exclusion criteria

Exclusion criteria: 1. Patients who refuse to give consent. 2. Patients with diagnosed CVA with unilateral or bilateral neurological deficit. 3. Patients with Segmental instability. 4. Patients with severe degenerative disc disease with more than 2/3rd of disc height decreased. 5. Patients allergic to the drugs we use. 6. Active infection at the site of injection. 7. Pregnancy.

Design outcomes

Primary

Measure	Time frame
Fluoroscopic assessment of feasibility, accuracy & safety of ultrasound guided supraneural & infraneural transforaminal nerve root injectionsTimepoint: During Procedure	—

Secondary

Measure	Time frame
1. To assess the accuracy of USG guided needle placement by fluoroscopy. 2. To assess the Pain relief by verbal numeric pain scale 3. Patient satisfaction in view of return to his/her routine work. 4. To assess the complications i.e. accidental intra- vascular, intraneural or subarachanoiod injection associated with US-guided transforaminal nerve root injections. Timepoint: 2 hours after the procedure, 1 week, 3 weeks, 6 weeks & 3 months	—

Measure

Time frame

1. To assess the accuracy of USG guided needle placement by fluoroscopy. 2. To assess the Pain relief by verbal numeric pain scale 3. Patient satisfaction in view of return to his/her routine work. 4. To assess the complications i.e. accidental intra- vascular, intraneural or subarachanoiod injection associated with US-guided transforaminal nerve root injections. Timepoint: 2 hours after the procedure, 1 week, 3 weeks, 6 weeks & 3 months

—

Countries

India

Contacts

Public ContactJoshva Saveriyar

Dr Rajendra Prasad Goverment Medical College

drbharti203@gmail.com9418044928

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026